Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.

Blonde L, Rosenstock J, Del Prato S, Henry R, Shehadeh N, Frias J, Niemoeller E, Souhami E, Ji C, Aroda VR

Diabetes care17 Sept 2019Cited by 75 (Europe PMC)

PMID31530665DOI10.2337/dc19-1357PepBankPUB-31530665

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

01HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In patients with diabetes, pooled continued GLP-1 agonists including dulaglutide reduced HbA1c less than switching to iGlarLixi.
In plain wordsIn patients with diabetes, pooled continued GLP-1 agonists including dulaglutide reduced HbA1c less than iGlarLixi.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c
Study
n = 514
Comparator
Switching to insulin glargine plus lixisenatide
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c at baseline
7.8%
both groups
HbA1c at 26 weeks
7.4%
continued GLP-1 RA (pooled, includes dulaglutide)
HbA1c at 26 weeks
6.7%
iGlarLixi
Least squares mean difference in HbA1c
−0.6%
iGlarLixi versus continued GLP-1 RA
Source sentences
Summary
iGlarLixi (n = 257) reduced HbA_1c more than continued GLP-1 RA therapy (n = 257) from a baseline 7.8% (62 mmol/mol) in both to 6.7% (50 mmol/mol) and 7.4% (57 mmol/mol), respectively, at 26 weeks (least squares mean difference -0.6%; P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or weekly GLP-1 RA therapy.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3153066501
02HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In patients with diabetes, pooled continued GLP-1 agonists including dulaglutide achieved the HbA1c target less often than iGlarLixi.
In plain wordsIn patients with diabetes, pooled continued GLP-1 agonists including dulaglutide achieved the HbA1c target less often than iGlarLixi.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c target attainment
Study
n = 514
Comparator
Switching to insulin glargine plus lixisenatide
Outcome group
Glycemic control · Metabolic and weight
Measurements
Patients reaching HbA1c <7%
26%
continued GLP-1 RA (pooled, includes dulaglutide)
Patients reaching HbA1c <7%
62%
iGlarLixi
Source sentences
Summary
More iGlarLixi patients achieved HbA_1c P 1c <7% without documented symptomatic hypoglycemia (<54 mg/dL).
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or weekly GLP-1 RA therapy.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3153066502
03HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In patients with diabetes, pooled continued GLP-1 agonists including dulaglutide achieved the glucose target without symptomatic hypoglycemia less often than iGlarLixi.
In plain wordsPooled continued GLP-1 agonists including dulaglutide achieved the glucose target without symptomatic low blood sugar less often than iGlarLixi.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c target without symptomatic hypoglycemia
Study
n = 514
Comparator
Switching to insulin glargine plus lixisenatide
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
More iGlarLixi patients achieved HbA_1c P 1c <7% without documented symptomatic hypoglycemia (<54 mg/dL).
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or weekly GLP-1 RA therapy.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3153066503
04HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In patients with diabetes, nausea rates were lower with pooled continued GLP-1 receptor agonists (including dulaglutide) than with switching to iGlarLixi.
In plain wordsIn patients with diabetes, nausea rates were lower with pooled continued GLP-1 receptor agonists (including dulaglutide) than with switching to iGlarLixi.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseNausea
Study
n = 514
Comparator
Switching to insulin glargine plus lixisenatide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Nausea and vomiting rates as well as numbers of documented symptomatic hypoglycemia events per patient-year were generally low but greater with iGlarLixi versus continued GLP-1 RA therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or weekly GLP-1 RA therapy.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3153066504
05HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In patients with diabetes, vomiting rates were lower with pooled continued GLP-1 receptor agonists (including dulaglutide) than with switching to iGlarLixi.
In plain wordsIn patients with diabetes, vomiting rates were lower with pooled continued GLP-1 receptor agonists (including dulaglutide) than with switching to iGlarLixi.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseVomiting
Study
n = 514
Comparator
Switching to insulin glargine plus lixisenatide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Nausea and vomiting rates as well as numbers of documented symptomatic hypoglycemia events per patient-year were generally low but greater with iGlarLixi versus continued GLP-1 RA therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or weekly GLP-1 RA therapy.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3153066505
06HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In patients with diabetes, documented symptomatic hypoglycemia events per patient-year were lower with pooled continued GLP-1 receptor agonists (including dulaglutide) than with switching to iGlarLixi.
In plain wordsIn patients with diabetes, documented symptomatic hypoglycemia events per patient-year were lower with pooled continued GLP-1 receptor agonists (including dulaglutide) than with switching to iGlarLixi.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDocumented symptomatic hypoglycemia
Study
n = 514
Comparator
Switching to insulin glargine plus lixisenatide
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Nausea and vomiting rates as well as numbers of documented symptomatic hypoglycemia events per patient-year were generally low but greater with iGlarLixi versus continued GLP-1 RA therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or weekly GLP-1 RA therapy.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3153066506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02787551

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Sanofin = 5146 Jul 2016 to 17 Nov 2018

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 25 Mar 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 6 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 4 times, first on 27 Oct 2026, 18:19 UTC. The status did not change between them.
Study results updated
Version 5
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 4
22 Oct 2026, 02:26 UTC
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.